Andras Heczey, MD, on Antitumor Activity of CAR NKTs in Solid Tumors

Video

The director of the Liver Tumor Program at Texas Children’s Hospital discussed a phase 1 study of CAR NK T-cells in neuroblastoma.

"With natural killer T-cells, or NK T cells for short, we have the ability to use a homogeneous population of effector lymphocytes that are able to effectively traffic into the tumor sites better than just conventional T cells... They can recognize cancer supportive tumor associated macrophages... and specifically target them. So that provides a big opportunity for NK T cell-based therapeutics to make a major impact in the treatment of solid tumor patients.”

Chimeric antigen receptor (CAR) natural killer (NK) T-cell therapy is well-tolerated with promising responses in patients with neuroblastoma, according to data from a phase 1 study (NCT03294954) presented by Andras Heczey, MD, Associate Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine at the American Society of Gene & Cell Therapy 25th Annual Meeting (ASGCT), held in Washington, DC, and virtually May 16-19, 2022.

Heczey and colleagues found that antitumor activity was associated with dosage and in vivo rate of expansion after treating 12 patients in 4 dose levels of 3x106 CAR+ NKTs/m2, 1x107 CAR+ NKTs/m2, 3x107 CAR+ NKTs/m2, and 1x108 CAR+ NKTs/m2 following lymphodepletion. Of these patients, 5 had progressive disease, 4 had stable disease, 2 had a partial response, and 1 had a complete response. No dose limiting toxicities or serious toxicities related to treatment were observed.

CGTLive spoke with Heczey to learn more about the phase 1 study and trends observed with antitumor activity. He discussed challenges with treating solid tumors and more research to be done.

REFERENCE
Herczey A, Courtney A, Ghatwai N, et al. Anti-GD2 CAR NKT cells are safe and produce antitumor responses in patients with relapsed/refractory neuroblastoma. Presented at ASGCT 25th Annual Meeting May 16-19, 2022, Washington DC. Abstract #54
Related Videos
Vivien Sheehan, MD, PhD, an associate professor of pediatrics at Emory University
Deepak L. Bhatt, MD, MPH, MBA
John A. Charlson, MD
Jeffrey Chamberlain, PhD
David Porter, MD
Judy Lieberman, MD, PhD, the endowed chair in cellular and molecular medicine at Boston Children’s Hospital
Jonathan W. Weinsaft, MD
Omid Hamid, MD
Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital
Robert J. Hopkin, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.